Bayer(US:BAYRY) Sou Hu Cai Jing·2025-10-23 12:18Group 1 - Chengdu Haibowei Pharmaceutical Co., Ltd. has successfully completed over 200 million yuan in Series B financing, led by Huagai Capital with participation from Yuan Sheng Venture Capital, Daoyuan Capital, and Panlin Capital, while existing shareholder Xincheng Fund increased its investment [1] - The funds from this round of financing will primarily be used for clinical research of innovative drugs HBW-004285, HBW-012336, HBW-012462, HBW-3220, and HBW-3210, as well as advancing multiple preclinical innovative drug development pipelines [1] - Haibowei Pharmaceutical, established in January 2019, is a high-growth high-tech enterprise focused on innovative drug research and development, with a registered capital of 7.1642 million yuan [1] Group 2 - The company employs nearly 100 staff, with over 80% being research and development personnel, and has over 10 innovative drug development pipelines covering urgent therapeutic areas such as tumor resistance, tumor immunity, pain, central nervous system, autoimmune diseases, and fungal infections [1] - Dr. Li Yingfu, the founder and chairman of Haibowei Pharmaceutical, has nearly 30 years of experience in drug research and management, having worked over 10 years in Bayer's drug research centers in Germany, Japan, and the United States, and is the first inventor and project leader of several Class 1 clinical new drugs [3]